Michio Sawada
Gifu-shi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Real-world comparison of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone and anthracycline-based regimens in peripheral T-cell lymphoma: A multicenter retrospective study from the Gifu Hematology Study Group.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: July 30, 2026
Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study.
Journal: Annals of hematology
Published: July 13, 2025
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal: Hematological oncology
Published: May 21, 2025
A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Journal: Hematological oncology
Published: June 11, 2023
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Journal: Scientific reports
Published: February 10, 2023
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma.
Journal: Leukemia & lymphoma
Published: December 30, 2021
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Journal: Experimental hematology & oncology
Published: October 26, 2021
Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi-institutional randomized controlled trial.
Journal: International journal of cancer
Published: July 22, 2020
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Journal: Hematological oncology
Published: August 03, 2017
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Journal: Hematological oncology
Published: July 10, 2015
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Journal: Hematological oncology
Published: June 09, 2015
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Journal: European journal of haematology
Published: May 10, 2013
Last Updated: 09/26/2026